Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
This finding applies to those who begin treatment with progressive liver fibrosis, or scarring.
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Individuals who experience a rapid undetectable viral load on a triple regimen of hepatitis C drugs may only need three weeks of treatment.
Bristol-Myers Squibb’s daclatasvir, asunaprevir and beclabuvir cured high rates of hepatitis C virus (HCV) among those with genotype 1...
BMS has resubmitted an application to the FDA for approval of daclatasvir, this time in combination with Sovaldi (sofosbuvir), to treat genoty...
The FDA intends to rescind the “breakthrough” designation for Bristol-Myers Squibb’s hepatitis C therapy daclatasvir.
The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston included a trove of good news for people...
The FDA has requested additional data from BMS about the hepatitis C drug daclatasvirâ€™s use in combination with other direct-acting...
Twelve weeks of BMS’s ?TRIO? combo pill, with ribavirin, cured 93 to 98 percent of people with genotype 1 of hep C who had cirrhosis in a rece...
Twelve weeks of BMS’s TRIO combo pill cured 91 percent of people with genotype 1 of hepatitis C who didn’t have cirrhosis in a recent trial.
Bristol-Myers Squibb has decided to end its pursuit of an approval for the hepatitis C therapy asunaprevir in the United States.
Bristol-Myers Squibb’s daclatasvir and asunaprevir cured 81 percent to 87 percent of people with genotype 1b of hepatitis C in a recent Phase...
As a new crop of hepatitis C therapies likely hits the market this fall, Gilead Sciences is poised to continue dominating the field.
The required treatment length to achieve a cure for hep C has recently shortened dramatically and may continue to taper in the coming years.
With interferon quickly becoming a thing of the past, what kind of side effects still remain in the new hepatitis C regimens?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.